Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction

Abstract

IMPORTANCEDetermining the characteristics, type, and severity of olfactory dysfunction in patients with long COVID is important for the prognosis and potential treatment of the affected population. OBJECTIVE To describe the sociodemographic and clinical features of patients with long COVID who develop persistent olfactory dysfunction. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study, conducted at a rehabilitation center at a public university in the Amazon region of Brazil between September 9, 2020, and October 20, 2021, comprised 219 patients with long COVID and self-reported neurologic symptoms. Of these 219 patients, 139 received a diagnosis of chronic olfactory dysfunction, as confirmed by the Connecticut Chemosensory Clinical Research Center (CCCRC) test. EXPOSURE Clinical diagnosis of long COVID.MAIN OUTCOMES AND MEASURES Electronic case report forms were prepared for the collection of sociodemographic and clinical data. Patients' sense of smell was evaluated via a CCCRC test, and the association of olfactory dysfunction with aspects of daily life was recorded using a questionnaire. RESULTSOf the 219 patients included in the study, 164 (74.9%) were women, 194 (88.6%) were between 18 and 59 years of age (mean [SD] age, 43.2 [12.9] years), 206 (94.1%) had more than 9 years of education, and 115 (52.5%) had a monthly income of up to US $192.00. In the study group, 139 patients (63.5%) had some degree of olfactory dysfunction, whereas 80 patients (36.5%) had normosmia. Patients with olfactory dysfunction had a significantly longer duration of long COVID symptoms than those in the normosmia group (mean [SD], 242.7 [101.9] vs 221.0 [97.5] days; P = .01). Among patients with anosmia, there was a significant association between olfactory dysfunction and daily activities, especially in terms of impairment in hazard detection (21 of 31 patients [67.7%]), personal hygiene (21 of 31 patients [67.7%]), and food intake (21 of 31 patients [67.7%]). Univariable logistic regression analyses found that ageusia symptoms were associated with the occurrence of olfactory dysfunction (odds ratio [OR], 11.14 [95% CI,.07]; P < .001), whereas headache (OR, 0.41 [95% CI, 0.22-0.76]; P < .001) and sleep disorders (OR, 0.48 [95% CI, 0.26-0.92]; P = .02) showed an inverse association with the occurrence of olfactory dysfunction. CONCLUSIONS AND RELEVANCEOlfactory dysfunction is one of the most important long-term neurologic symptoms of COVID-19, with the highest prevalence seen among women, adults, and outpatients. Patients with olfactory dysfunction may experience persistent severe hyposmia or (continued) Key Points Question What are the sociodemographic and clinical characteristics of patients with long COVID and persistent olfactory dysfunction? Findings In this cross-sectional study of 219 patients with long COVID and neurologic symptoms, 64% had olfactory dysfunction, with the highest prevalence among women, adults, and outpatients. Patients with olfactory dysfunction may develop severe olfactory loss (hyposmia or anosm...

Association of viral variant and vaccination status with the occurrence of symptoms compatible with post-acute sequelae after primary SARS-CoV-2 infection

“…One study demonstrated the persistence of memory problems at 18 months after mild SARS-CoV-2 infection and another showed that 38% of infected patients still reported symptoms at 23 months after infection 25,26 . In addition, some authors have suggested that loss of smell/taste, which was one of the symptoms showing a clear association with PASC in our study, might potentially be a permanent sequela after COVID-19 27 . Further research aiming at mitigating the PASC burden in those infected early on in the pandemic is urgently needed.…”

Choroid Plexus Modulates Subventricular Zone Adult Neurogenesis and Olfaction Through Secretion of Small Extracellular Vesicles

“…Olfactory disorders represent a highly prevalent early-onset symptoms in several neurodegenerative disorders, particularly in Alzheimer’s disease (Murphy 2019; Pacyna et al 2022; Tian et al 2022) and Parkinson’s diseases (PD) (both idiopathic and Mn-induced) (Doty 2012; Lucchini et al 2009). Disturbed olfaction is also one of the prominent leading symptoms associated with post-COVID conditions (Boscolo-Rizzo et al 2022; Mendes Paranhos et al 2022). Interestingly, severely disrupted function of the CP in humans has been associated with pathological progressions in AD, frontotemporal dementia, Huntington’s disease, and severe COVID19 (Kant et al 2018; Stopa et al 2018; Tadayon et al 2020; Yang et al 2021).…”

Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders

“…The clinical presentation is highly diverse, involving several organs and systems. Smell and taste disorders were particularly frequent since the initial phase of the COVID-19 pandemic (19, 20), with quantitative (hypo-, hyper-, anosmia or ageusia) or qualitative (dys-, phantosmia or phantageusia) alterations. Persistent olfactory disorders have been notified from 10% to more than 50% according to SARS-CoV-2 variants (18, 19), and can be recovered in a few months.…”